In Brief: Anika Therapeutics
This article was originally published in The Gray Sheet
Executive Summary
Anika Therapeutics: Plans to file a premarket approval application with FDA "by the end of the year" for its Orthovisc intra-articular hyaluronic acid injection for treatment of osteoarthritis of the knee. Results of a just-completed randomized clinical study of 226 patients conducted at 10 centers in the U.S. are "promising," the firm states. Two HA products for osteoarthritis of the knee recently received FDA approval -- Fidia's Hyalgan and Biomatrix' Synvisc ("The Gray Sheet" Aug. 18, p. 6)...